Cellzome AG

Cellzome AG is a company in Heidelberg, Germany that has taken part in 3 EU-funded projects since 2011, receiving €1.5M in EU funding.

EU funding received€1.5M
EU projects3
As coordinator0
Running now0
First EU project2011
Latest project2012
CountryGermany
EU registration (PIC)989438025
On this page · 5 sections→

Where the EU money came from

Funding by EU programme. Amounts are Cellzome AG's own share of each project, not the project's full budget.

  • FP7 (2007 to 2013)€1.5M · 3 projects

Projects

3 EU-funded projects, newest first. Each links to the official record.

  • OVER-MYRPartner

    Overcoming clinical relapse in multiple myeloma by understanding and targeting the molecular causes of drug resistance

    FP7 (2007 to 2013) · 2012–2015 · Project on CORDIS ↗

  • BLUEPRINTPartner

    A BLUEPRINT of Haematopoietic Epigenomes

    FP7 (2007 to 2013) · 2011–2016 · Project on CORDIS ↗

    €1.2Mtheir share
  • ORCHIDPartner

    Open Collaborative Model for Tuberculosis Lead Optimisation

    FP7 (2007 to 2013) · 2011–2015 · Project on CORDIS ↗

    €300ktheir share

Works most with

Organisations that shared the most EU projects with this one. A good starting list for consortium partners.

Fields it works in

Research fields recorded on its Horizon projects.

  • autoimmune diseases
  • drug discovery
  • drug resistance
  • epigenetics
  • genomes
  • leukemia
  • tuberculosis

Is this your organisation?

Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.

Claim this profile →

Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗

Europe’s tech funding.
One place.

The weekly briefing

Funding calls, VC news and key deadlines — a weekly briefing for European founders.

Free · unsubscribe anytime